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MYBL1 IN TRIPLE NEGATIVE BREAST CANCER PATIENT TISSUES
By
Tyra Ivory, M.S.
Texas Southern University, 2022
Associate Professor Audrey Player, Ph.D., Advisor
The aggressive behavior in triple negative breast cancer (TNBC) is due to genetic
signaling events, which call for the comprehensive analyses of genes differentially
regulated in the cancers. Our laboratory previously found that MYBL1 was over-expressed
in a fraction of the TNBC, compared to some luminal, and other breast cancer subtypes.
The MYBL1 gene is a proto-oncogene that serves as a strong transcriptional activator. The
gene is involved in signaling events related to cell cycle signaling, differentiation,
proliferation, and apoptosis, all which are differentially regulated in cancers. Because
MYBL1 is a transcription regulator, involved in cancer related mechanisms and
differentially expressed in TNBC, our lab designed studies to better characterize the gene
in TNBC. We performed shRNA lentiviral knockdown of MYBL1 in TNBC as the first
goal to identify genes directly or indirectly affected by knockdown of the MYBL1 gene in
these cancers. Our hypothesis is that some (not all) genes identified by this method likely
cooperate with MYBL1 to affect the genotype and phenotype of TNBC. The TCF19 and
KIF18b genes were two of the first candidate genes identified in our knockdown study.
1
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When MYBL1 was knocked down, TCF19 and KIF18b were also downregulated.
Although we performed preliminary analyses of TCF19 and KIF18b RNA transcript levels
in cell lines and using online patient datasets, a main goal of the current study was to
examine TCF19 and KIF18b protein expression in clinically diagnosed TNBC (tissue)
patient samples. We want to view, in situ, the protein level of our candidate genes in tissue
samples isolated from women with clinically described breast cancer. Since TCF19 and
KIF18b genes are downregulated when MYBL1 is knocked down, we will determine if
these genes are co-expressed in the same tissue samples as MYBL1 protein. We also
expand our bioinformatic analyses of the three genes, but the focus is protein analyses of
MYBL1, TCF19 and KIF18b in patients’ tissues with defined clinical diagnoses.
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CHAPTER 1
INTRODUCTION
Background Information About Breast Cancer and Summary of Breast Cancer
Types
Breast cancers, like all cancers grow uncontrollably, the cells undergo differentiate
processes, and ultimately the cells metastasize (i.e., travel) from the primary organ to
distant tissues (3, 24). Although women are primarily affected by breast cancer, men are
also affected. The origin of the cancer, its classification as invasive or non-invasive, and
the molecular receptor status of the cancer cells are the key signatures that determine the
type of cancer, the prognosis, and treatment options. For breast cancer, the cancers
originate in the breast, and for some the progenitor cell types are luminal, myoepithelial,
and basal-like cells that line the lumen. Researchers conclude that progenitor cells along
with their microenvironment lead to the heterogeneity of breast cancers.
All cancers including breast cancers are extensively heterogeneous. Breast cancers
are characterized based on their pathological diagnoses and molecular signatures
(http://www.breastcancer.org/symptoms/types)

(38).

Pathological

diagnoses

are

performed by clinicians and DNA microarray assay is the most common experimental
method utilized to define the molecular characterization of breast cancers. Microarrays can
concurrently identify the transcript levels of thousands of genes, allowing researchers to
define signaling pathways associated with particular cell types. Microarrays have also been
1
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instrumental in identifying

genes useful for targeted therapies. We have briefly

summarized breast cancers categorized based on pathology and molecular signatures in the
section below. These data emphasize the heterogeneity of breast cancers.
As a general description, benign tissues are non-cancerous, generally not harmful
and do not expand beyond their original site of origin. Invasive cancers metastasize from
their site of origin to other organs, making them malignant and life-threatening. Cancers
that leave and return to the same or different location in the body are called reoccurring
cancers.
Detailed list of pathologically diagnosed types of breast cancers: Even though
there are many types of breast cancer in this category, most of them are rare. The cancers
are listed alphabetically.
Cribriform Carcinoma of the Breast: Cribriform cancers are rare invasive
cancers. The cancers are low grade (i.e., look normal), but appear to have ‘holes’ or display
cribriform-like configurations.
Ductal Carcinoma in Situ (DCIS): DCIS is a non-invasive, non-metastatic
carcinoma which originates in the milk ducts of the breast. It occurs at a rate of ~15%.
DCIS patients have a significant risk of developing invasive cancers.
Inflammatory Breast Cancer (IBC): IBC is a rare invasive cancer that is very
aggressive. IBC is difficult to detect and treat because of it appears as “sheets” rather than
“lumps” like most other breast cancer types.
Invasive Ductal Carcinoma (IDC): IDC occurs at a rate of 60-70% making it the
most common type of breast cancer. It occurs in the milk ducts and is defined as an invasive
cancer.
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Invasive Lobular Carcinoma (ILC): ILC cancers is the second most common
breast cancer based on pathology, occurring in approximately 15% of patients. ILC cancers
are invasive cancers that originate in the lobules of the breast.
Lobular Carcinoma in Situ (LCIS): LCIS are often call lobular neoplasia. LCIS
grows in the milk glands (i.e., lobules). It is defined as an abnormal, benign cell growth,
but patients have a high risk of developing invasive cancer.
Male Breast Cancer: Breast cancer in men is a very rare often invasive cancer.
The cancers occur in less than 1% of men.
Medullary Carcinoma of the Breast: Medullary carcinomas are rare invasive
ductal carcinomas that occur in approximately 3% of patients. Its name originates from its
appearance. Medullary carcinomas appear as soft, flesh-like masses that resemble the
medulla of the brain. Medullary carcinomas are genetically similar to TNBC.
Mucinous Carcinoma of the Breast: Mucinous Cancer is a rare cancer that
originates in the milk ducts. Pathologists characterize the appearance as ‘abnormal cells
floating in a pool of mucin’, hence the name.
Paget’s Disease of the Nipple: Paget’s disease is a breast cancer in which the
cancer cells are localized to the nipple and breast ducts. Regions around the nipple are
inverted, hardened resembling eczema and dermatitis.
Papillary Carcinoma of the Breast: They are a rare invasive cancer localized to
the ductal region of the breast cancer. Papillary cancers have small finger-like projections
or papules, hence the name.
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Phyllodes Tumors of the Breast: Phyllodes tumors are rare cancers occurring in
~1% of patients. The tumor cells grow in a leaf-like pattern. Unlike most breast cancers,
phyllodes cancers originate from cells in the stromal regions in the breast tissue.
Tubular Carcinoma of the Breast: Tubular breast cancer originates in the milk
ducts of the breast and are a subtype of invasive ductal breast cancer, hence the tumors are
invasive. Microscopically, the cancers look like tubes. They account for less than 2% of
breast cancers.

Molecular Breast Cancer Types
Breast cancers are also characterized based on their molecular signatures. Defining
breast and other cancers based on molecular signatures came much later than pathological
descriptions. High throughput genomic and transcriptome assays were instrumental
towards accurate molecular analyses of cancers. The definitions and the incidence of
occurrence of molecular breast cancers are summarized in Figure 1. A more elaborate
description is given at this reference (https://www.breastcancer.org/symptoms/types) (26).
Some breast cancers are referred to as luminal or triple negative / basal-like subtypes. These
designations are based on the location of the progenitor cells for luminal and triple
negative/basal-like cancers as shown in Figure 2 (49).

Molecular Subtypes of Breast Cancer are Luminal A/B, Triple Negative/Nasal-like,
HER2-enriched, and Normal-like
According to Yersal et al. (52), luminal A cancers are defined as estrogen receptor
positive, progesterone receptor positive, and HER2 negative. Luminal B are classified as
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estrogen receptor positive, progesterone receptor positive, and HER2 positive or negative.
Luminal B cancers versus Luminal A cancers only slightly differ in prognoses. Triple
negative/basal-like cancers are estrogen receptor, progesterone receptor, and HER2
negative (7, 10). TNBC and basal-like are often classified together, but data show there is
~25% difference between them. Our laboratory studies TNBC and the cancers are
extensively described below. HER2neu-enriched breast cancers are estrogen receptor
negative, progesterone receptor negative, and HER2 positive. Normal-like cancers are
similar to Luminal A cancers based on estrogen receptor positive, progesterone receptor
positive, and HER2 negative status; but the cancers differ in the display low Ki67 levels
and they are low grade (28).
Triple Negative Breast Cancer
The progenitor cells for TNBC are localized to the basement region of the luminal
region of the milk duct and the progenitor cells for luminal cancers are nearest the actual
lumen (Figure 2) (7). Prior to studies by Lehmann et al (34) TNBC were defined as a single
subtype. Lehmann et al used DNA microarray and showed that TNBC could be further
divided into 6 sub-categories, each defined by specific gene expression profiles. Lehmann
et al (34) defined the subtypes as (a) Luminal androgen receptor (LAR) also known as
molecular apocrine cancers, (b) basal-like 1 (BL1), (c) basal-like 2(BL2), (d) an
immunomodulatory group (IM), (e) a mesenchymal group (M), and (f) a mesenchymal
stem-like sub-group (MSL). The LAR subcategory includes estrogen receptor samples that
overexpress androgen receptors and hormonal regulatory genes. The basal-like 1 (BL1)
group is enriched in genes associated with the ribonucleic acid (RNA) polymerase
pathway, cell cycle and cell division signaling pathways. The basal-like 2 (BL2) sub-
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category are suspected of originating from the myoepithelium and genes associated with
this sub-category are involved with growth factor signaling processes, gluconeogenesis,
and glycolysis. Immunomodulatory (IM) cancers are similar to medullary breast cancers.
They are enriched with genes that include immune signaling pathways, natural killer cell
pathways, cytokine signaling pathways, and antigen identification and processing
pathways. The M and MSL sub-category include genes aligned with cell motility,
proliferation, mesenchymal-like differentiation, and extracellular matrix proteins. Since
Lehmann et al (34) subdivided TNBC, a substantial number of potential biomarkers and
improvements in predictive targeted therapies have been identified.

Figure 1:

Molecular Signatures and Prevalence of Breast Cancer Types (26)
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Figure 2:

Anatomical Position of Luminal Breast Cancer vs TNBC Progenitor
Cells Near Breast Lumen
Luminal subtype progenitor cell= luminal epithelial; TNBC subtype
progenitor cells= basal cell types (7).

Breast Cancer Statistics and Other Information Related to TNBC
According to The American Cancer Society, breast cancer is the most common
cancer in women, besides skin cancers (5). About 281,550 new cases of invasive breast
cancer will be diagnosed in women in 2021 and approximately 43,600 women will die
from the disease. Women of African descent have a higher rate of occurrence and death
rate compared to women of Caucasian / European. The disparities between the races is
thought to be due to genetics and socio-economic conditions related to lack of adequate
health care unique to women of African descent. Patients that die from cancers are either
diagnosed with later stage or they have a cancer that has limited therapeutic options (10).
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Considering the entire TNBC subtype, the cancers account for 15-20% of breast
cancers (41). The TNBC are aggressive cancers and have a shorten 5-year survival rate
compared to other types of breast cancers (1, 2). Also compared to other breast cancers,
there are fewer treatment options available for TNBC patients. Patients with receptor
positive breast cancers are treated with hormone or therapies that target estrogen receptors
(ER) or human epidermal growth factor receptors 2 (HERS). Because TNBC patients lack
the positive receptors, they cannot benefit from these targeted therapies. TNBC patients
rely on the more general, less specific chemotherapy and radiation treatment strategies.
Our research focuses on characterizing MYBL1 and other genes differentially associated
with TNBC with the goal that we will identify genes useful to study as targeted therapy for
TNBC.

CHAPTER 2
LITERARY REVIEW
Discovery of the MYB Oncogene Family
The MYB gene family consists of c-MYB, MYBL1, and MYBL2 genes and more
recently have been referred to as “emerging players and potential therapeutic targets in
human cancer” (12). This study is designed to further characterize MYBL1 in TNBC. The
MYB family of genes are strong transcription factors that remain relatively unchanged
from plants to animals, confirming their essential roles in different organisms. The MYB
family of genes were identified in humans because of their close similarity to the Avian
Myeloblastiosis virus (AMV) v-MYB gene sequence (19). The v-MYB gene was initially
identified as the product of the retroviral oncogene that causes leukemia in birds. The cMYB gene was the first of the human MYB genes identified, based on its similarity the vMYB sequence, while the MYBL1 and MYBL2 were identified based on their similarity
to c-MYB. Data suggest the MYBL2 is the most ancient member of the family, since
studies have shown that invertebrates carry a MYB gene, that is phylogenetically and
functionally like MYBL2. Sequence analyses reveal both similar and divergent regions in
all three MYB family genes. Similarly, the MYB family genes can transcriptionally
regulate some of the same and different genes. Each of the MYB family genes interact with
different co-factors, suggesting they can also regulate different genes (44).
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MYB Family Sequences Comparison to Highlight Shared Gene and Unique Gene
Expressions
MYBL1, MYBL2, and c-MYB, are all involved in controlling cell survival,
proliferation, and differentiation. Although the MYB family genes have similarities in their
sequence, there are also contrasting regions between the three genes (20). All MYB genes
possess an N-terminal DNA binding domain (DBD), internal transactivation domain, and
C-terminal regulatory domain. The domains are responsible for characterizing their
recognition sites, protein interactions with other transcription factors and coactivators, and
sites susceptible to epigenetic modifications. The DBD, which is responsible for binding
to DNA, is a highly conserved helix-turn-helix (HTH) domain at the N-terminus region of
all three MYB genes (53).

The transactivation and C-terminal regulatory domain

demonstrate less homology between the genes. Researches suggest that differences in
recognition and post-translational modification of these sequences lead to differential gene
expression and subsequence signaling mechanisms (43, 44).
Using the DNA foot-printing assay, Ness et al identified the DNA recognition
sequence (which he termed the MYB-binding site) for all MYB proteins (37). The binding
region is a part of the activation and transcriptional repressor complexes and is estimated
to be ~90% similar between the MYB family. These data suggest that MYB family genes
can recognize some of the same genes. Ultimately, the transcriptional behavior of MYB
proteins is regulated either positively or negatively by co-factors.
The MYB family proteins contain another domain that is responsible for proteinprotein interaction called the SANT domain. The SANT domain was identified based on
its homology to the c-MYB DBD (9). SANT is an acronym for Swi3, Ada2, N-Cor, and
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TFIIIB genes; the first genes identified with the motif. Although the SANT domain is
similar to the DBD, SANT is a protein: protein interaction domain allowing for histone
binding, chromatin remodeling and transcriptional regulation.
Relationship of MYBL1 to Cell Signaling
MYBL1 is a proto-oncogene that is associated with key cellular functions such as
cell regulation, proliferation, differentiation, and apoptosis, events which are important to
cancer (25). MYBL1 is expressed in all tissues, but particularly in the central nervous
system, germinal-B lymphocytes, mammary gland ductal epithelium, and in the testis (4,
27, 31). Studies show the MYBL1 gene is associated with growth abnormalities, defects in
spermatogenesis, and female breast developmental processes. MYBL1 is highly
transcribed in spermatocytes undergoing meiosis. Utilizing a MYBL1-null mice with a
focus on processes associated with spermatogenesis, Bolcun-Filas et al (4) found that
deficiency in MYBL1 expression led to a disruption in cell cycle associated genes and
specifically prophase I of the cell cycle, leading to infertility in mice. They concluded that
MYBL1 was a master regulator of meiotic genes particularly those required for cell cycle
progression through the pachynema stage of prophase I.
Aside from spermatocytes, the MYBL1 gene is a critical part of the DREAM or
LINC complex which together regulate cell cycle signaling processes (16-18) involved in
G1/S and G2/M phases of the cell cycle in all cell types. The DREAM complex is an
acronym for dimerization partner, RB-like, E2F and multi-vulval class B. The complex is
comprised of interactions between “elongation factor 4 (E2F4), elongation factor 5 (E2F5),
LIN9 complex DREAM MuvB core complex component (LIN9), Lin-37 DREAM MuvB
Core Complex Component (LIN37), Lin-52 DREAM MuvB Core Complex Component(
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LIN52), Lin-54 DREAM MuvB Core Complex Component (LIN54), MYBL1, MYBL2,
Retinoblastoma-Like 1 Protein (RBL1), Retinoblastoma-Like 2 Protein (RBL2),
Retinoblastoma Binding Protein 4 (RBBP4) , Transcription Factor Dp1 (TFDP1) and
Transcription Factor Dp2 (TFDP2) proteins” (17). Various interactions between these
genes are involved in regulation of G1/S and G2/M phases of the cell cycle processes in
nearly all cell types. Validating the association of MYBL1 with the DREAM complex and
involvement with cell cycle, when we knocked down MYBL1 in TNBC we found an
enrichment in the differential expression of DREAM associated genes summarized above.

Relationship of MYBL1 to Tumorigenesis
Before considering MYBL1 for its role in cancers, a vast number of studies were
performed to consider c-MYB gene as a target for breast cancer (22, 23, 36). The c-MYB
gene was first considered because (like MYBL1) it is involved in cell differentiation,
proliferation and apoptosis, all of which are key to cancer pathogeneses. Only more
recently has MYBL1 been considered as a biomarker for cancers. Data show MYBL1
dysregulation in TNBC (40), breast Adenoid Cystic Carcinomas (which is a rare TNBC;
31) and leukemias (21). The precise mechanism that leads to changes in MYBL1
expression are not defined, but when changes are defined, often the gene is amplified
leading to over-expression or in the case of Burkitt’s lymphoma, defined by a MYB-NFIB
fusion gene translocation event (27).
MYBL1, MYBL2, TCF19, and KiF18b Genes Screened as Part of this Study
Data is mounting in support of the role of MYB proteins in cancers. Because we
(a) performed meta-analyses and found MYBL1 differentially expressed in a
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subpopulation of TNBC, and (b) MYBL1 can transcriptionally regulate a host of genes
related the cancer processes, we decided to knockdown MYBL1 in TNBC (39).
Knockdown studies allow us to identify genes that are either directly or indirectly affected
by the MYBL1 transcription factor and cooperate with the gene to affect TNBC genotype
and phenotype. The first genes screened for their possible role with MYBL1 in TNBC were
the TCF19 and KIF18b genes. Our knockdown analyses showed MYBL2 (a MYB family
member) was also downregulated when MYBL1 was knocked down, so this gene was
included in many of our analyses. Still, the primary focus of the current study is to compare
the protein expression patterns of MYBL1, TCF19 and KIF18b genes in clinically
diagnosed TNBC tissue samples. We want to view the protein levels of these genes in real
breast cancer patient samples to see if TCF19 and KIF18b are expressed in the same tissue
sections, indicating co-expression.

TCF19 Gene
The TCF19 gene is being examined to determine if it is co-expressed with MYBL1.
The gene was substantially downregulated following MYBL1 lentiviral knockdown. As a
result, the gene was screened for its role in TNBC because it demonstrates a similar pattern
of expression with MYBL1 and MYBL2 following analyses of gene expression. TCF19
gene is a transcription factor so it is localized predominantly to the nucleus compartments
of the cell. Little is known about the TCF19 gene, but studies show it is associated with
both proliferation and apoptosis in insulinoma cells (30). Early data showed the gene was
expressed in both mouse and human islets, with increasing mRNA expression in
nondiabetic obesity. Krautkramer et al found that following siRNA-mediated knockdown
of TCF19 gene in the pancreatic tumor INS-1 β-cell line, the cells displayed a decrease in
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proliferation and an activation of apoptosis. Microarray analyses of the dataset showed an
enrichment in differential expression of cell cycle genes from the late G1 through M phase
and G1/S checkpoint genes. These data suggest a role of TCF19 in proliferation and cell
cycle regulation and proliferation, similar to the MYBL1 transcription factor signaling
mechanisms (30).

KiF18b Gene
Kinesin Family Member 18B (KIF18B) gene is downregulated when MYBL1
lentiviral knockdown was performed, as a result the gene was screened for its pattern of
expression as part of the current study. The gene is localized in the cytosol, nucleus, and
cytoskeleton compartments of the cell. KIF18B is a tumor-associated gene that is involved
in the carcinogenesis of multiple malignancies (33). KIF18B is a motor protein that is
involved in microtubule-associated-chromosomal-movement during mitosis. KIF18B
knockdown in breast cancer cells showed the cells displayed a reduction in proliferation,
invasion, and epithelial-mesenchymal transition and enhanced chemosensitivity to
Doxorubicin (45). The same studies show that over-expression of KIF18b correlates with
low survival in breast cancer. In another study, Li et al (35) performed a meta-analysis of
the expression of the kinesin superfamily genes in breast cancer. The authors find that
KIF18b is overexpressed in basal/TNBC, and that over-expression of the gene correlates
with worse overall survival; they recommend the gene be considered as a potential
prognostic biomarker.

CHAPTER 3
DESIGN OF THE STUDY
Cell Lines - Patient Clinical Samples - Bioinformatic Datasets
The breast cell lines utilized in this study were purchased from the American Type
Culture Collection (ATCC®) atcc.org and utilized within 1 year of purchase. The cell lines
are MCF10A (benign triple negative), MCF7 (receptor positive), and MB231 (TNBC). The
cells were maintained using Dulbecco’s Modified Eagle Minimum essential media
(DMEM) supplemented with 1% penicillin and 10% serum, fed twice per week and
incubated in a 37ºC incubator with 5% CO2. The cells were grown to 80-90% confluency
and either used for RNA extraction or collected for sub-culture using a 0.25% trypsin
solution.
The tissue microarray (TMA) samples were purchased from BioMaxUS. TMAs are
small tissue sections generated from 100’s of patient biopsies, in this case breast cancer
biopsies. At a preparation facility (i.e., company), the tissues are fixed in formaldehyde,
embedded in paraffin, sectioned, and adhered to a microscope slide. A picture of a TMA
is included below in this document. TMAs allow the researcher to analyze hundreds of
patients for expression of a single antibody / protein in the time it takes to process 1 tissue
microscrope slide. Sample BR1509 was selected and purchased (from BioMax.US) for this
study. The TMA slide contained ~125 TNBC patient samples previously diagnosed by
15
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pathologists. Patient biopsy samples used to generate the BR1509 array were anatomized,
and information related to age, receptor status, sex and clinical stage were included. Protein
analyses of TMAs was performed using immunohistochemistry (IHC) analyses.
For the bioinformatic analyses (which is separate from the TMA analyses), the
cBioportal.org (11) online database was utilized. cBioPortal contains thousands of curated
pan-cancer and breast cancer patient samples which we analyzed for MYBL1, TCF19,
KIF18b (and MYBL2) mutation frequency and gene expression frequencies.

Ribonucleic Acid (RNA) Isolation
The cell lines in this study were grown to approximately 90% confluency in T75
dishes and harvested by adding 1 mL Trizol to the culture dish. Two hundred microliters
(ul) of chloroform was added to the trizol/ sample mixture. The suspension was mixed and
centrifuged at 12,000 revolutions per minute (RPM) to separate the aqueous RNA layer.
The RNA layer was added to a separate tube and 500 μL of 95% ethanol was added and
the mixture stored at -20ºC for 30 minutes. The RNA was collected by centrifuging the
samples for 30 minutes at 10,000 RPM. The RNA pellet was desiccated, resuspended in
20 μL of clean water and heated at approximately 60ºC for 1 minute. Approximately 2ul
of the RNA solution was added to RNA sample buffer and loaded on a 1% RNA gel to
assess the integrity of the ribosomal RNA. The gel was prepared by adding 1 gram of
agarose to a 1x solution of 3-(N-morpholino) propane sulfonic acid (MOPs) buffer, 2 uL
of 7% formaldehyde and 2 μL of ethidium bromide. The RNA sample was considered
acceptable for downstream use if the 28S/18S ribosome RNA bands were observed at equal
density.
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Generating Complementary DNA (cDNA)
The iScript cDNA kit from Bio-Rad (Bio-Rad, Hercules CA, USA) was used to
generate cDNA. A 20 μL mixture containing RNA, 5x iScript buffer (with random
hexamers, oligo dT, reverse transcriptase buffer and dNTPs), reverse transcriptase enzyme
and water was prepared and placed at 45ºC for an hour. The reverse transcriptase enzyme
was inactivated by heating the mixture at 85ºC for 1-2 minutes. The mixture was chilled
and 80 μL of water was added. The cDNA mix was stored at –20ºC until it was utilized for
polymerase chain reactions (PCR) or -80 degrees for long term retention.

Process for Generating Primers
The primer3 (29) program (http://bioinfo.ut.ee/primer3-0.4.0/) was used to generate
primers for each of the target genes: TCF19, KIF18B, MYBL2, MYBL1 and GAPDH
control gene. Affymetrix NetAffx (15) was used to obtain the nucleotide sequences of our
target genes (http://www.affymetrix.com/estore/analysis/index.affx). The default program
was used to generate all gene primers; the size of the amplicon (which ranged from 200300 nucleotides for each gene) was the only parameter changed in the default program. The
University of California Santa Cruz’s Genome database (48) (https://genome.ucsc.edu/) in
silico PCR analyses program was used to validate the specificity of the primer-sets. The
primer-set sequences were manufactured by IDTDNA.com (Coralville, Iowa), then
shipped to Texas Southern University within 48 hours of online purchase. Table 1 displays
the primer sequences for the genes used in this study.
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Table 1: Primer Sequences Corresponding to Each of the Genes Used in This
Study for PCR Analyses

Polymerase Chain Reaction (PCR)
The PCR procedure was used to observe the contrasting levels of gene expression
in particular samples. PCR was also used to validate the microarray results. The PCR
reactions consisted of 2 μL of forward and reverse gene primers (~0.5uM), cDNA, 10 μL
of 2x DNA polymerase I TAQ polymerase master mix (containing TAQ enzyme, dNTPS
and TAQ buffer) (Life Technologies, Carlsbad, California), and water to final 20ul volume.
The samples were placed in PCR quality tubes and amplified using the Bio-Rad Thermal
Cycler (Hercules California). The cycle conditions were (a) 5 minutes at 95ºC degrees (b)
30-32 cycles for 30 seconds at 95ºC, followed by 30 seconds at 58ºC degrees, then 30
seconds at 78ºC.
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Gel Electrophoresis
The PCR products were analyzed by separation on a 2% agarose gel for
electrophoresis. The gel consisted of 100 mL of 1X Tris/Borate/EDTA (TBE) buffer with
2 grams of agarose. The mixture was heated, cooled, and 1 μL of Ethidium Bromide (EtBr)
was added prior to pouring the gel mixture into the gel chamber. To allow direct
comparisons between transcript levels, exactly 10 μL of the PCR product and 2 μL of the
sample buffer were loaded to the gel chamber for electrophoresis.
Densitometer
To visualize the PCR products on the gel, LI-COR Imaging System (Lincoln
Nebraska) is used. The LI-COR Analysis software was used to determine the density of
the PCR amplicons visible on the agarose gel. The densities of the amplified amplicons
were calculated by comparing the ratio of the intensity of the gene product/GADH loading
control. The numeric values related to the amplicon intensities were obtained using the LICOR Analysis software.
Protein Interaction Analyses
To examine and determine if our genes/proteins were ‘in any way’ related, the
Search Tool for the Retrieval of Interacting Genes/Proteins (STRINGTM) (46) online
program was utilized. STRINGTM analysis is a database that integrates millions of bits-ofknowledge obtained from citations, experimental analyses and other databases to
determine direct (physical) and indirect (functional) associations between genes/proteins.
Based on this information, known and predicted protein-protein interactions and signaling
events can be revealed. This software was used to establish interactions between MYBL1
and MYBL2, and TCF19 and KIF18B.
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Immunohistochemistry Staining
A thin paraffin embedded TNBC TMA (BR1509) was purchased from BioMax.US
for this study. The TMAs were deparaffinized and subsequently rehydrated by placing the
slides in 2 separate xylene baths for 15 minutes each, then rehydrated by placing the tissues
in 100%, then 95%, then 70% alcohols, then clean water for 15-minute increments each.
The slides were then rinsed with PBS for 5 minutes. Antigen retrieval was performed by
placing the TMAs in a boiling solution of 1x citrate solution (H-3300-250, Vector
Laboratory, Burlingame CA) for 20minutes. The slides were again rinsed with PBS for 5
minutes. The TMAs were incubated with the antibody blocking serum (normal horse
serum; supplied with PK-6000; ABC HRP peroxidase staining kit, Vector Laboratory) at
room temperature for 30 minutes. Excess antibody blocking serum was discarded and the
tissues along with their coinciding antibody were incubated at 4ºC overnight. The PK-6000
ABC-HRP kit was used for day 2. As summary, the slides were washed, incubated with
the biotin-conjugated secondary universal antibody for 30 minutes, washed, incubated with
Avidin-biotin-peroxidase 30minutes, washed, incubated with 3,3′-Diaminobenzidine
(DAB) solution, washed and counterstained with hematoxylin. The signal intensities were
scored from 1+ to 3+++. No evidence of a positive signal was scored as zero. The CD31
blood vessel antibody is utilized as a control because vessels are present in all tissues.
CD31 protein was also important to use as an assessment of tissue quality. If the tissue is
of poor quality, CD31 would be negative and excluded from analyses.

CHAPTER 4
RESULTS AND DISCUSSION
This chapter discusses the materials and procedures performed prior to this study
and is critical to interpretation of the results. The data generated as part of the initial
study is shRNA knockdown of MYBL1 in MB231 cells.
The knockdown study was performed to further characterize TNBC and determine
genes that were directly or indirectly affected by knockdown of MYBL1 in the TNBC. The
TCF19 and KIF19B genes were identified following analyses of genes affected by shRNA
knockdown of MYBL1 in TNBC cells. A brief description of how specific genes-ofinterest were combined with lentiviral to generate viral particles suitable for transduction
(of target cells) is summarized in Figure 3 (47). Gene of interest and the needed elements
for RNA production and packaging are infected with HEK cells. Prior to being sent to
customers for transduction, the encased particles are developed and harvested. In this
figure, the HEK293T cells are utilized to produce viral particles that are converted into
cardiomyocyte cells (47).

21

22

Figure 3:

Summary of the shRNA Procedure

We purchased 4 MYBL1 shRNA lentiviral particle preps and 1 scramble control
particle prep (ready for transduction) from Origene (Cat# TL303089V; Rockville,
Maryland). The lentiviral particles were packaged in the pGFP-C-shLentiviral vector
(labeled LVA, LVB, LVC, LVD) Table 2. The particles were ready for transduction into
TNBC cells when they arrived. We only had to transduce the preps (at a MOI of 1:10) and
test which was more effective at knocking down MYBL1. LVA lentiviral particles with
the TCTGATCCTGTAGCATGGAGTGACGTTAC sequence, revealed significant
downregulation of the MYBL1 mRNA. For this reason, the LVA particles were used for
future experiments. Each was transduced into MYBL1 and assessed for knockdown of
MYBL1 transcript. LVA was most successful at decreasing MYBL1 transcript.
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Table 2: shRNA MYBL1 Target Sequences

Western Blotting:
The western blot procedure was performed as outlined in a previous publication
(39). As noted, the antibodies used for the assay are summarized below: Antibodies: Both
antibodies described below were developed as mouse monoclonals. Actin was used at a
1:104 dilution (NB600-501SS; Novus Biologicals LLC, Littleton CO), and MYBL1 was
used at a 1:500 dilution (sc-514682; Santa Cruz Biotechnology, Santa Cruz CA).
Secondary HRP conjugated Anti mouse antibody (HAF007; R and D Systems,
Minneapolis, MN) was used at a dilution of 1:4000. Western blotting results were observed
with the Clarity Western ECL substrate (Bio-Rad, Hercules, CA, USA) on a LICOR digital
imaging system (LI-COR Biotechnology, Lincoln, NE).
RNA and protein analyses of the LVA shRNA MYBL1 particles displaying
knockdown of MYBL1 RNA and protein in MDA MB231 cells are displayed in Figure 4.
PCR transcript (RNA) and Western blot (protein) were utilized to distinguish MYBL1
levels in MDA MB231 cells transduced with scramble compared to LVA particles
compared to untreated MDA MB231 cells.
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Figure 4:

Analyses of LVA Sequence Ability to Knowdown Transcript and
Protein Levels

RNA was purified from the scrambled and the MYBL1 knockdown preparations of
MDA MB231 cells. The RNAs were shipped overnight to the University of Texas
Southwest (UTSW; Dallas Texas, USA). The UTSW core facility validated the purity of
the RNA, converted the preparations to antisense-RNA and hybridized it to the Affymetrix
Clarion microarray gene-chip which is composed of >186,000 probe-sets (i.e., transcripts,
splice variants, miRNA, and snoRNA) (see figure 5). The UTSW facility provided our
laboratory with the hybridization results. The data analyses were performed (at TSU) by
Dr. Player utilizing the Affymetrix TAC 4.0 software (ThermoFisher Scientific, Waltham
Massachusetts). The data were normalized using the Robust Multi Array (RMA) program
and the Limma Bioconductor analysis was used to determine the differently expressed
genes/ probe-sets. If the probe-sets showed at least a 4-fold contrasting gene expression
between scrambled probe-set values and the MYBL1 LVA microarray dataset, the gene
was selected for further analysis. A 2-fold difference is the industry standard, but an
increase in the cut-off leads to a more reliable dataset. Gene Ontology analysis (8) was
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used to investigate the differentially expressed candidate genes. Microsoft excel was used
to

generate

the

transcript

plots.

The

Molbio

online

tool

(http://www.molbiotools.com/listcompare.html) was used to compare the differentially
expressed gene-lists.
As shown in Figure 5 sense strands complementary to the target sequence were on
the genechip. Gene-chips were composed of either 56,000 transcripts or 186,000
transcripts, splice variants and small RNAs are displayed as blue/white dots in the center
figure. Antisense-RNA is tagged and hybridized to the genechip. High copy number
transcripts are displayed as white dots, low copy number as blue/black dots (see far right
pane). Control sequences at determined concentrations are also on the given gene-chip and
used to correlate copy number with signal intensities (15).

Figure 5:

The Affymetrix Microarray Genechip

Based on differential gene expression analyses, comparisons to existing cell line
and patient sample datasets and bioinformatic analyses, TCF19 and KIF18b genes were 2
of the genes chosen as candidate genes. Since MYBL1 is a transcription factor, we asked
of the genes on our list, including TCF19 and KIF18b, which ones are direct transcriptional
targets of MYBL1’? The ChipX (32) program show that MYBL1 (via promoter binding
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assessment) interacts with TCF19 and KIF18b genes. Table 3 shows that out of 1632
transcription factors, MYBL1 ranked 11th in binding TCF19 and KIF18b. It was these
types of data that supported our selection of TCF19 and KIF18b genes for further studies.
CHipX can validate the presence of MYBL1 binding sequences and its ability to bind the
promoter region of TCF19 and KIF18b (50); we did not confirm the cell type used to
demonstrate actual binding.
Table 3: Transcription Factor Enrichment Analyses Using ChipX
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Results and Discussion
The focus of our laboratory was to further characterize MYBL1 gene in TNBC cells
and patient samples. MYBL1 is a strong transcription activator associated with regulation
of cell cycle signaling. We recognized that we could ask a host of different questions to
help characterize MYBL1, but our major concern was ‘to identify genes that might be
either directly or indirectly cooperating with MYBL1 to affect the genotype and phenotype
of TNBC’. To achieve this goal, we knocked down MYBL1 in a TNBC cell line, and
identified genes significantly affected by decreased expression of MYBL1 based on T-test
analyses (39). As expected, the MYBL2 gene, which is closely related to MYBL1 in
sequence, protein interaction mechanisms and signaling processes, was also
downregulated. The other family member, c-MYB is not expressed in these cells, hence it
was not affected. A substantial number of genes were affected by the knockdown, including
TCF19 and KIF18b.
Choosing which genes to analyze and validate can be an arduous task; this can be
less difficult by applying bioinformatic analyses. We chose to begin our studies with
validation of MYBL1, MYBL2, TCF19 and KIF18 (jointly) because of CHipX and
STRINGTM (46; Figure 6). STRINGTM analyses suggest the genes are related based on
mitotic and dimerization partner, RB-like, E2F and multi-vulval class B (DREAM)
complex signaling mechanisms (17). Together, all 4 genes were involved in mitosis and
cell cycle regulation. More specifically, TCF19 was involved in G1 to S phase progression
(54) similar to MYBL1. KIF18b is a member of the kinesin family of proteins involved in
microtubule interactions necessary for mitotic cell division. Little is known about the direct
association between MYBL1 and KIF18b, but data show MYBL1 and MYBL2 can bind
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to the promoter region and regulate KIF18b (32, 33, 50) subsequently regulating gene
expression. STRINGTM analyses was generated by entering (only) MYBL1, MYBL2,
TCF19 and KIF18b; the LIN37, LIN9, FOXM1, KIF2C, CCNB1 genes were ‘occupied’
based on published data which demonstrated a statistically significant relationship between
all 9 genes. STRINGTM analyses show the genes have a strong relationship mostly based
on PubMed citations. See the low false discovery rates. Coupled with our other analyses,
these analyses help with our decision to study TCF19 and KIF18b. Table 4 is a summary
of the genes examined in this current study.

Figure 6:

STRINGTM Analyses Demonstrating Interactions Between MYBL1,
MYBL2, TCF19 and KIF18b
Protein interactions as documented between MYBL1, MYBL2, TCF19 and
KIF18b.

29

Table 4:

Summarized Genes Description of Candidate Genes and effect
Following Knockdown of MYBL1

This study is in the preliminary stages of validating genes affected by knockdown
of MYBL1. The goal was to identify and characterize genes that cooperate with MYBL1
gene to influence the genotype and phenotype of TNBCs. The primary aim of this current
study was to focus on validation of the protein expression levels of these genes in patient
samples characterized by their receptor status and pathological diagnoses. The
experimental approach was to examine the protein levels of TCF19 and KIF18b genes in
patient samples diagnosed as TNBC, supplied as a high throughput tissue microarray
(TMA). As a result, antibodies were used to detect in situ protein levels in paraffin
embedded tissues. As far as we are aware, MYBL1 protein levels have never been
documented in TNBC patient samples. So, these data should be important for
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demonstrating the genes’ pattern of protein expression in TNBC patients. The experiments
will be repeated and expanded in future experiments. The MYBL2 gene was also
downregulated following knockdown of MYBL1, but we could not find a commercial
antibody that would hybridize to MYBL1 proteins in paraffin embedded tissues; this is not
uncommon for antibodies. As a result, the full summary of the current project is to (a)
examine TCF19 and KIF18b protein levels in the TNBC (patient) tissue microarrays (b)
examine these same samples for MYBL1 protein levels for comparison and (c) expand
bioinformatic analyses of MYBL1, MYBL2, TCF19 and KIF18b in patient samples
available as high throughput (online) datasets. The transcript PCR analyses was repeated
as validation of the differential expression of MYBL1, MYBL2, TCF19 and KIF18b in the
MDA MB231 TNBC cell line.
This study was separated into 2 sections. The first section includes the
immunohisto-chemistry protein analyses, and the second section included our further
validation of the use of MYBL1 as a differential gene candidate for breast and pan cancers.
RNA transcript validations were included in the first section.
Section 1- protein (and RNA) Analyses of the Genes of Interest
Choice of Cells Lines Used for the Transcript Analyses Utilizing the PCR Assay
There are at least 92 breast cancer and non-tumorigenic breast cell lines available
for studying breast cancer (14). The cell lines are well established and many of them are
available from the American Type Culture Collection. The cells have been extensively
characterized based on their original source, genotype and molecular signatures, response
to therapies and pathology to name just a few distinctions. The focus of our laboratory is
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to characterize TNBC, so we chose MDA MB231 cells as our primary cell line because the
cells are well characterized and results from our laboratory can be readily compared to
published datasets as validation. The MCF10A are chosen because the cells are triple
negative non-tumor and serve as a suitable non-tumor comparison. The MCF7 cell lines
serve as a receptor-positive comparison (to the receptor negative, TNBC). We are aware
that breast cancers are incredibly heterogenous and we have defined future experiments to
address and examine the molecular diversity of breast cancers.
PCR Transcript Analyses MYBL1, MYBL2, TCF19 and KIF18B in Breast Cell
Lines
Previous data show that MYBL2, TCF19 AND KIF19b transcripts are
downregulated when MYBL1 gene is knocked down in MBA MB231 cells. These data
suggest that MYBL2, TCF19 and KIF18b genes are over-expressed in untreated MDA
MB231 cells and either directly or indirectly regulated by MYBL1 gene. Figure 7 further
validates the differential pattern of expression of MYBL1, MYBL2, TCF19 and KIF18b
in MCF10a compared to MCF7 and MDA MB231 cells. In Figure 7 the GAPDH gene was
utilized as control: a) gel electrophoresis of the PCR analyses of transcript levels, and (b)
represents the densitometer analyses of the gel profile. The values presented for the
densitometer figure were calculated based on the ratio of the gene/GAPDH intensity for
each cell line. Higher levels of the gene transcripts are detected in MCF7 and MDA MB231
compared to MCF10a non-tumor triple negative cells.
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Figure 7:

PCR RNA Transcript Analyses of MYBL1, MYBL2, TCF19, KIF18b in
MCF10a, MCF7 and MDA MB231 Cell Lines
a) gel electrophoresis of the PCR analyses of transcript levels, and
b) represents the densitometer analyses of the gel profile

Immunohistochemistry Protein Analyses of TNBC
A. Use of the Tissue Microarray for Analyses of Protein Expression in Paraffin
Embedded Sections
Breast samples making up the tissue microarrays (TMA) were collected from
female patients previously diagnosed with invasive ductal carcinomas; nearly all tissue
samples (used to construct the TMA) were collected from TNBC patients. Before being
used for the TMA, patient samples were collected as round-cylinder-like sections (i.e.,
cores) from individual paraffin embedded patient tissue blocks. The resulting TMA (with
individual patient samples) was supplied on conventional microscope slides, allowing for
easy manipulation. The TMAs were constructed such that each slide represented an exact
‘positional replicate’ of the patient samples. For this study, TMAs were incubated
separately with either CD31 (blood vessel control), MYBL1, KIF18b or TCF19 antibodies,
allowing for in situ detection of protein expression (Figure 8). Because the TMAs
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contained large numbers of tissues per slide, they allowed for analyses of hundreds of
patient samples for expression of at least one protein.
A summary of the protein expression of CD31 blood vessel control TMA, the
MYBL1 TMA, the KIF18b TMA compared to TCF19 TMA are given in Table 5. One
hundred twenty- five samples (on the TMA) were of suitable quality, as determined by
detection of CD31 control. Overall, significantly more TNBC patient samples showed
evidence of MyBL1 protein expression than TCF19 or KIF18b.
•

Based on patient’s age at diagnoses- MYBL1 protein was detected at a higher
percentage in patients >50 years old. KIF18b protein was detected at a slightly
higher percentage in patients younger than 50 years old, but overall, both
KIF18b and TCF19 were detected at lower percentages than MYBL1. Many
of the same patient samples expressing KIF18b and TCF19, were positive for
MYBL1.

•

Based on the pathological stage of the patient sample - MYBL1 protein was
detected at a higher percentage in the earlier stages (i.e., 1 and 2) compared to
KIF18b and TCF19 proteins. There weren’t enough stage 3 patients to draw
conclusions. This was a bit confusing because earlier studies suggest MYBL1
was expressed in more differentiated tissues. Emphasizing the need to expand
this study.

•

Based on receptor status of the patient sample- MYBL1 protein was detected
at a higher percentage in TNBC compared to KIF18b and TCF19. Many of the
KIF18b and TCF19 patients were positive for MYBL1 protein. There were
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only 3 Her2 positive patient samples; there was questionable expression of
MYBL1, KIF18b and TCF19, so the tissues were not scored.
•

Based on KI67 expression of the patient sample- Ki67 is utilized as an
indicator of cellular proliferation. A higher percentage of MYBL1 was
detected in patients demonstrating high proliferation (i.e., in Ki67 high
expression). Compared to KIF18b and TCF19, a higher percentage of MYBL1
positive patients were found to demonstrate increased proliferation.

For several samples, there was evidence of inflammatory-looking cells in the
stromal regions that were positive for MYBL1 (13), TCF19 (51) and KIF18b (42). These
observations are consistent with the data showing infiltration of inflammatory cells with
tumor progression.
Table 5:

Summary of the TMA Immunohistochemistry Results
Based on in situ Detection of CD31, MYBL1, KIF18b and TCF19 Protein,
Based on the Patients’ Age, Clinical Stage, Receptor Status and KI67
Protein Expression
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Figure 8 is an example of the tissue microarrays with individual TNBC patient
samples on the conventional microscope slide. Each purple dot/core represents a patient
sample. For analyses of protein expression, 4 separate TMAs were incubated with CD31
or MYBL1 or KIF18b or TCF19 antibody. The order/arrangement of the patient samples
is exactly the same on each slide allowing for direct comparison of protein expression in a
particular patient core. Tissue microarray: a rapidly evolving diagnostic and research tool.
Nazar MT, Annals of Saudi Medicine 2 April 2009. https://doi.org/10.4103/02564947.51806.

Figure 8:

B.

Example of the Tissue Microarrays with Individual TNBC Patient
Samples on the Conventional Microscope Slide

Immunohistochemistry Images Demonstrating Protein Levels in TNBC,
Invasive Ductal Carcinomas
DAB (brown color) was utilized for colorimetric detection and subsequent

localization of the protein levels in TNBC patient samples. CD31 (a protein predominately
localized to blood vessels) was utilized as control. Even though the TMA contained 150
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patient samples, only those with suitable CD31 expression (i.e., intensity levels 1+ to
3+++) were utilized for this study. The different patient ‘cores’ utilized to construct the
TMA were obtained from tissue blocks that might have sat on a shelf for years. As example,
some patient samples might have been collected and embedded in paraffin 5 years ago, and
other patient samples might have been collected and embedded in paraffin 20 years ago.
So, protein levels in the samples collected 20 years ago might have declined compared to
the samples collected 5 years ago. Under these conditions, the 5-year-old ‘core’ might
present with higher CD31 control protein level intensities; this explains why control and
overall protein intensities vary.
MYBL1 and KIF18b IHC Analyses
Figures 9 and Figure 10 represent patient samples assessed for expression of
MYBL1, KIF18b and CD31 protein levels. The two figures represent 2 different patient
samples with a similar pattern of MYBL1 and KIF18b protein expression. MYBL1 gene
is a transcription factor, and its protein levels are localized mostly in the nucleus. Protein
expression in the nuclear regions give the appearance of brown ‘dots’. MYBL1 protein is
also present predominately in the epithelial tumor cells. There are lower levels of the
protein detected in the stromal regions of the tissue. The precise nature of these cells was
not determined, but based on their size and location, they were likely inflammatory in
nature. There is evidence that MYBL1 regulates proliferation of leukocytes (13), so
positive cells in the stromal region of these samples might be leukocytes. For the two
patient samples in Figure 9 and Figure 10, KIF18b protein was not detected. CD31 control
demonstrate substantial expression in blood vessels of the tissue; note the large blood
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vessel staining brown. Positive CD31 means the tissue is good quality, so negative KIF18b
signal is not related to poor tissue quality.
Figure 9 shows that the MYBL1 levels were detected and KIF18b levels were
negative. MYBL1 nuclear staining appears as brown ‘dots’. The same section showed
evidence of CD31 control (i.e., blood vessels). 10X magnification. Figure 10 shows that
MYBL1 levels were detected and KIF18b levels were negative. MYBL1 nuclear staining
appears as brown ‘dots’. The section showed evidence of CD31 blood vessels control. 10X
magnification.
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Figure 9:

IHC analyses of MYBL1, KIF18b and CD31 Control Protein Levels in
Invasive Carcinoma TNBC Samples
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Figure 10: IHC Analyses of MYBL1, KIF18b and CD31 Control Protein Levels in
Another Invasive Carcinoma TNBC Sample
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The pathology of the tissue represented in Figure 11 is different from that observed
in the previous figures. The breast tumor cells of this patient lack organization (which is
related to differentiation). MYBL1 levels were easily detected as nuclear (i.e., as
represented by a pattern of dots). Again, KIF18b protein was not detected in this patient.
MYBL1 levels were detected and KIF18b levels were negative. MYBL1 nuclear staining
appears as brown dots. All sections showed evidence of CD31 control (i.e., blood vessels).
10X magnification.
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Figure 11: IHC Analyses of MYBL1, KIF18b and CD31 Control Protein Levels in
Invasive Carcinoma TNBC Samples
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When KIF18b was detected, low levels were observed (Figure 12 and Figure 13).
The gene appeared to be confined to particular regions of the tissue. Previous data show
that KIF18b protein is expressed in nuclear or cytoplasmic regions of the cell (33). Only
the cytoplasmic staining patterns for the gene was observed. There was no observation of
the tissues that were positive for KIF18b and negative for MYBL1. There were examples
of tissues (of suitable protein quality as determined by positive CD31 expression) that were
negative for both MYBL1 and KIF18b (Figure 14). Although this sample appeared
negative (for MYBL1 and KIF18b), we labeled this patient as ‘questionable’.
Figure 12 is the IHC analyses of MYBL1, KIF18b and CD31 control protein levels
in invasive carcinoma TNBC samples. MYBL1 and KIF18b levels were detected. MYBL1
nuclear staining appeared as brown dots. KIF18b staining the far-right region. All sections
showed evidence of CD31 control (i.e., blood vessels). 10X magnification.
Figure 13 is the IHC analyses of MYBL1, KIF18b and CD31 control protein levels
in another invasive carcinoma TNBC samples. MYBL1 and KIF18b levels were detected.
MYBL1 nuclear staining appeared as brown dots. KIF18b staining the far left and right
region. All sections showed evidence of CD31 control (i.e., blood vessels). 10X
magnification.
Figure 14 is the IHC analyses of MYBL1, KIF18b and CD31 control protein levels
in invasive carcinoma TNBC samples. MYBL1 and KIF18b levels were not detected. All
sections showed evidence of CD31 control (i.e., blood vessels). 10X magnification.
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Figure 12: IHC Analyses of MYBL1, KIF18b and CD31 Control Protein Levels in
Invasive Carcinoma TNBC Samples
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Figure 13: IHC Analyses of MYBL1, KIF18b and CD31 Control Protein Levels in
Another Invasive Carcinoma TNBC Samples
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Figure 14: IHC Analyses of MYBL1, KIF18b and CD31 Control Protein Levels in
Invasive Carcinoma TNBC Samples
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MYBL1, TCF19 and KIF18b IHC Expression
Several samples on the TMA were positive for TCF19 expression. TCF19 is a
transcription factor, so nuclear staining (ie, a brown dot pattern) is expected. Patient sample
in Figure 15 tissue was positive for MYBL1 and TCF19 expression and negative KIF18b
expression. MYBL1 and TCF19 were detected and KIF18b levels was not detected.
MYBL1 and TCF19 nuclear staining- brown dots (b) the same sample demonstrating
TCF19 compared to CD31 for this patient. 10X magnification. Figure 16 tissue shows
positive TCF19 expression compared to CD31 for the same patient sample at 10X
magnification.
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Figure 15: IHC Analyses of MYBL1, TCF19, KIF18b and CD31 Control Protein
Levels in Invasive Carcinoma TNBC Samples
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Figure 16: IHC analyses of TCF19 and CD31 Control Protein Levels in Invasive
Carcinoma TNBC Samples
Figure 17 shows a patient sample that is negative for MYBL1 and positive for
TCF19. MYBL1 background levels are high, and there is no evidence of positive nuclear
staining, hence MYBL1 protein expression. There was, however, evidence of TCF19
nuclear staining (and CD31 staining) in the patient sample. The tumor cells comprising this
sample are ‘well organized’. This same tissue is negative for KIF18b (Figure 17). Figure

49

18 is the IHC analyses of MYBL1, KIF18b and CD31 control protein levels in invasive
carcinoma TNBC samples. MYBL1 and KIF18b are negative in this patient sample
compared to positive CD31 protein expression.

Figure 17: IHC Analyses of MYBL1, TCF19 and CD31 Control Protein Levels in
Invasive Carcinoma TNBC Samples
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Figure 18: IHC Analyses of MYBL1, KIF18b and CD31 Control Protein Levels in
Invasive Carcinoma TNBC Samples
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Summary of the IHC Results
This study is based on the hypothesis that MYBL1, TCF19 and KIF18b proteins
are co-regulated in TNBC, ultimately contributing to the TNBC genotype. To test the
hypothesis, our approach was to examine the in-situ pattern of protein expression of
MYBL1 compared to TCF19 and KIF18b in TNBC patient samples. Preliminary analyses
suggest that ‘to a large degree, protein levels in TNBC patient samples (for our panel of
genes) are not always co-expressed and are probably not involved in all of the same
signaling processes’. In other words, there was not complete concordance between
protein expression of the 3 genes. This inference is supported by the bioinformatic
analyses presented in Section 2 below. However, it did appear that many of the patient
samples were positive for MYBL1, further validating our selection of MYBL1 to study for
its involvement in TNBC. When KIF18b protein expression was observed, it did correlate
with tissues expressing MYBL1. When TCF19 protein expression was observed, it
correlated with and on one occasion without MYBL1 expression.
Even though we can summarize the data generated in this study, there are not
enough samples (per TMA) or clinical data to determine why some samples showed
evidence of MYBL1 (TDF19 or KIF18b) expression and some did not. We will repeat
these studies and increase the number of patient samples and clinical data provided per
TMA.
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Bioinformatic Analyses of MYBL1 in High Density Pan-tumors and Breast Cancer
Identified in cBioPortal
cBioPortal (11) is an online database which contains high throughput, curated
genomic, transcriptome and proteomic analyses from thousands of cancer patients. The
database contains information gathered from pan-cancers (i.e., all cancer types) and
individual cancer types generated using published information from researchers associated
with Memorial Sloan Kettering, Dana-Farber Cancer Institute, Children’s Hospital of
Philadelphia, and the Princess Margaret Cancer Institute (Toronto).
We have established that MYBL1 transcript and protein (to a lesser degree) are
differentially associated with a TNBC cell line and patient samples. We have less
information concerning the pattern of expression of the 4 gene panel of MYBL1, MYBL2,
TCF19 and KIF18b. This is an ongoing study, as a result, MYBL1, MYBL2, TCF19 and
KIF18b genomic alterations were assessed in the TCGA dataset which contains 2583
patients across various types of cancer (Figure 19). These data demonstrate MYBL1
genetic alterations in the form of amplifications and mRNA overexpression in 15% of the
cancers (that are examined). Some of the same samples demonstrate gene amplifications
in TCF19, KIF18b and MYBL2. See the region in the box. But note that a lower percentage
of cancers show evidence of MYBL2 and even fewer KIF18b and TCF19. Of the different
cancer types, genetic alterations are highest for the 4 gene-set in mature B-cell lymphoma,
colorectal, compared to esophagogastric followed by breast cancers (a). When alterations
based on MYBL1 gene (only) were accessed, the highest incidence was observed in mature
B-cell lymphomas followed by breast cancers compared the other cancer types (c).
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Analyses of breast cancers extracted from this dataset and analyzed for the 4 geneset show 20% of the breast cancers contain MYBL1 genetic alterations, with fewer samples
demonstrating an overlap with TCF19, KIF18b and MYBL2 genetic alterations (d). These
data suggest that MYBL1 is not co-regulated to a significant degree with MYBL2, TCF19
and KIF18b in these dataset. Based on statistical analyses, the incidence of MYBL1 in pancancers exceed the values expected had the event been a random occurrence. This dataset
also examined BRCA negative and subtype analyses. These data show a high incidence of
MYBL1 in BRCA Basal/TNBC consistent with our initial observations of MYBL1 in
TNBC.
Figure 19 (a, b, c, d) shows the pan-cancer analyses of TCGA dataset for analyses
of MYBL1, MYBL2, TCF19, KIF18b (i.e., 4 gene set) in all cancer types. The region in
the box represents samples ‘shared between MYBL1, MYBL2, TCF19 and KIF18b. As
shown in (b) the same samples analyzed in (a) was analyzed for MYBL1 only. Also, (c)
shows the TCGA dataset processing the breast cancer samples for MYBL1, MYBL2,
TCF19, KIF18b genetic alterations (d) is TCGA breast cancer datasets based on subtype
analyses of 4 gene-set.
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(a)

(b)

continued
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(c)

(d)
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Figure 19: Pan-cancer Analyses of TCGA Dataset for Analyses of MYBL1,
MYBL2, TCF19, KIF18b (i.e., 4 gene set) in All Cancer Types
(a) The region in the box represents samples ‘shared between MYBL1,
MYBL2, TCF19 and KIF18b.
(b) Same samples in (a) analyzed for MYBL1 only.
(c) TCGA dataset processing the breast cancer samples for MYBL1,
MYBL2, TCF19, KIF18b genetic alterations.
(d) TCGA breast cancer datasets based on subtype analyses of 4 gene-set.

CHAPTER 5
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
MYBL1 demonstrates a differential pattern of protein expression in TNBC invasive
carcinoma tissue sections. Fewer patient samples display expression of TCF19; one patient
sample displayed positive TCF19 and negative MYBL1. Substantial KIF18b protein levels
were not observed in the tissue sections. The 4 gene set did not demonstrate a precise
concordant expression in the tissue sections. For example, if 15-20% of the cancers display
MYBL1 expression, a similar % of cancers might be expected to show expression of
TCF19 and KIF18b. The signaling mechanisms are similar in some, but not all TNBC
patients.
These experiments must be repeated using a larger number of patient tissues that
contain more clinical prognostic data (i.e., survival, level of differentiation associated with
the patient’s cancer which is measure of tumor progression). A suitable MYBL2 antibody
must be identified to determine the comparative expression of MYBL2 in paraffin
embedded TNBC patient samples.
The results generated following bioinformatic analyses of the TCGA patient
datasets were consistent with the immunohistochemistry data. For example, MYBL1 is
expressed in patient samples, but TCF19, KIF18b and MYBL2 are expressed at lower
frequencies in the same tissues, and different patient samples.
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